Results 21 to 30 of about 1,512,475 (325)

Interim Estimates of Vaccine Effectiveness of Pfizer-BioNTech and Moderna COVID-19 Vaccines Among Health Care Personnel - 33 U.S. Sites, January-March 2021.

MMWR. Morbidity and mortality weekly report, 2021
Throughout the COVID-19 pandemic, health care personnel (HCP) have been at high risk for exposure to SARS-CoV-2, the virus that causes COVID-19, through patient interactions and community exposure (1).
T. Pilishvili, K. Fleming-Dutra, Jennifer L. Farrar, R. Gierke, Nicholas M. Mohr, D. Talan, A. Krishnadasan, K. Harland, H. Smithline, P. Hou, Lilly C. Lee, Stephen C Lim, G. Moran, E. Krebs, M. Steele, D. Beiser, Brett Faine, J. Haran, U. Nandi, W. Schrading, B. Chinnock, D. Henning, F. LoVecchio, J. Nadle, Devra M. Barter, Monica M. Brackney, Amber Britton, Kaytlynn Marceaux-Galli, Sarah Lim, Erin C. Phipps, G. Dumyati, Rebecca Pierce, Tiffanie M. Markus, D. Anderson, A. Debes, Michael Lin, J. Mayer, H. Babcock, N. Safdar, M. Fischer, R. Singleton, N. Chea, S. Magill, J. Verani, S. Schrag   +44 more
semanticscholar   +1 more source

Effectiveness of a Third Dose of Pfizer-BioNTech and Moderna Vaccines in Preventing COVID-19 Hospitalization Among Immunocompetent and Immunocompromised Adults — United States, August–December 2021

MMWR. Morbidity and mortality weekly report, 2022
COVID-19 mRNA vaccines (BNT162b2 [Pfizer-BioNTech] and mRNA-1273 [Moderna]) provide protection against infection with SARS-CoV-2, the virus that causes COVID-19, and are highly effective against COVID-19-associated hospitalization among eligible persons ...
M. Tenforde, Manish M Patel, M. Gaglani, A. Ginde, D. Douin, H. Talbot, J. Casey, N. Mohr, A. Zepeski, T. McNeal, S. Ghamande, K. Gibbs, D. Files, D. Hager, A. Shehu, M. Prekker, H. Erickson, M. Gong, A. Mohamed, N. Johnson, Vasisht Srinivasan, J. Steingrub, I. Peltan, Samuel M. Brown, E. Martin, A. Monto, Akram Khan, C. Hough, L. Busse, A. Duggal, Jennifer G. Wilson, N. Qadir, Steven Y. Chang, C. Mallow, C. Rivas, H. Babcock, Jennie H. Kwon, M. Exline, Mena M Botros, A. Lauring, N. Shapiro, N. Halasa, J. Chappell, Carlos G. Grijalva, T. Rice, I. D. Jones, William B. Stubblefield, A. Baughman, K. Womack, J. Rhoads, C. Lindsell, K. Hart, Yuwei Zhu, Eric A. Naioti, K. Adams, N. Lewis, D. Surie, M. McMorrow, W. Self   +58 more
semanticscholar   +1 more source

mRNA therapy restores euglycemia and prevents liver tumors in murine model of glycogen storage disease

Nature Communications, 2021
Glycogen Storage Disease 1a (Gsd1a) is an inherited disorder caused by glucose 6-phosphatase (G6Pase-α) deficiency and characterized by hypoglycaemia and high risk of liver cancer.
Jingsong Cao, Minjung Choi, Eleonora Guadagnin, Maud Soty, Marine Silva, Vincent Verzieux, Edward Weisser, Arianna Markel, Jenny Zhuo, Shi Liang, Ling Yin, Andrea Frassetto, Anne-Renee Graham, Kristine Burke, Tatiana Ketova, Cosmin Mihai, Zach Zalinger, Becca Levy, Gilles Besin, Meredith Wolfrom, Barbara Tran, Christopher Tunkey, Erik Owen, Joe Sarkis, Athanasios Dousis, Vladimir Presnyak, Christopher Pepin, Wei Zheng, Lei Ci, Marjie Hard, Edward Miracco, Lisa Rice, Vi Nguyen, Mike Zimmer, Uma Rajarajacholan, Patrick F. Finn, Gilles Mithieux, Fabienne Rajas, Paolo G. V. Martini, Paloma H. Giangrande   +39 more
doaj   +1 more source

Detailed Dissection and Critical Evaluation of the Pfizer/BioNTech and Moderna mRNA Vaccines

Vaccines, 2021
The design of Pfizer/BioNTech and Moderna mRNA vaccines involves many different types of optimizations. Proper optimization of vaccine mRNA can reduce dosage required for each injection leading to more efficient immunization programs. The mRNA components
X. Xia
semanticscholar   +1 more source

Vaccine efficacy against SARS-CoV-2 for Pfizer BioNTech, Moderna, and AstraZeneca vaccines: a systematic review

Frontiers in Public Health, 2023
The purpose of this systematic review was to report on the vaccine efficacy (VE) of three SARS-CoV-2 vaccines approved by Health Canada: Pfizer BioNTech, Moderna, and AstraZeneca.
Lia Reynolds, Cate Dewey, Ghaid Asfour, M. Little   +3 more
semanticscholar   +1 more source

UMA GRAMÁTICA MODERNA

Revista Projetar - Projeto e Percepção do Ambiente, 2021
Em teorias normativas ou prescritivas, os requisitos arquitetônicos são definidos como parâmetros para apoiar as decisões de projeto. Um conjunto de parâmetros formais é suficiente para gerar uma grande variedade de composições, quase sempre associadas a uma mesma linguagem formal.
Luiz Manuel do Eirado Amorim, Cristiana Griz, Yara Bezerra   +2 more
openaire   +3 more sources

Frailty impacts immune responses to Moderna COVID-19 mRNA vaccine in older adults

Immunity & Ageing, 2023
Background Immune responses to COVID-19 mRNA vaccines have not been well characterized in frail older adults. We postulated that frailty is associated with impaired antibody and cellular mRNA vaccine responses.
C. Semelka, Michael E. DeWitt, Maria W. Blevins, Beth C. Holbrook, J. Sanders, M. Alexander-Miller   +5 more
semanticscholar   +1 more source

Adverse Effects of Pfizer (BioNTech), Oxford-AstraZeneca (ChAdOx1 CoV-19), and Moderna COVID-19 Vaccines among the Adult Population in Saudi Arabia: A Cross-Sectional Study

Vaccines, 2023
The Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) outbreak has caused massive damage to the global healthcare system and economy. To compete with the SARS-COV-2 pandemic, several vaccines have been proposed to immunize the population.
J. Aldali, S. Meo, T. Al-khlaiwi
semanticscholar   +1 more source

Three-month antibody persistence of a bivalent Omicron-containing booster vaccine against COVID-19

Nature Communications, 2023
We previously presented day 29 interim safety and immunogenicity results from a phase 2/3 study (NCT04927065) comparing the Omicron-BA.1-containing bivalent vaccine mRNA-1273.214 (50-µg) to the 50-µg mRNA-1273 booster in adults who previously received ...
Spyros Chalkias, Charles Harper, Keith Vrbicky, Stephen R. Walsh, Brandon Essink, Adam Brosz, Nichole McGhee, Joanne E. Tomassini, Xing Chen, Ying Chang, Andrea Sutherland, David C. Montefiori, Bethany Girard, Darin K. Edwards, Jing Feng, Honghong Zhou, Lindsey R. Baden, Jacqueline M. Miller, Rituparna Das   +18 more
doaj   +1 more source

Analysing the In-Use Stability of mRNA-LNP COVID-19 Vaccines Comirnaty™ (Pfizer) and Spikevax™ (Moderna): A Comparative Study of the Particulate

Vaccines, 2023
Comirnaty™ and Spikevax™ were the first vaccines approved for human use based on modified non-replicating mRNA lipophilic nanoparticle (mRNA-LNP) technology, with great success in the treatment of COVID-19. They have been used massively worldwide. One of
J. Hermosilla, Airan Alonso-García, A. Salmerón-García, J. Cabeza-Barrera, A. Medina-Castillo, R. Pérez-Robles, Natalia Navas   +6 more
semanticscholar   +1 more source